Repligen (RGEN) to Release Earnings on Tuesday

Repligen (NASDAQ:RGEN) will likely be issuing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of $0.46 per share and revenue of $201.5920 million for the quarter. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. During the same period in the previous year, the company earned $0.39 earnings per share. Repligen’s revenue was up 14.8% compared to the same quarter last year. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Stock Performance

NASDAQ:RGEN opened at $131.96 on Monday. The company has a 50-day moving average of $131.68 and a 200-day moving average of $132.34. The firm has a market cap of $7.44 billion, a price-to-earnings ratio of 146.62, a price-to-earnings-growth ratio of 2.54 and a beta of 1.06. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $100.99 and a twelve month high of $175.77.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Repligen

A number of hedge funds have recently modified their holdings of the business. UMB Bank n.a. boosted its position in shares of Repligen by 13.8% in the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after buying an additional 92 shares during the period. CANADA LIFE ASSURANCE Co raised its position in Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after buying an additional 100 shares during the period. Itau Unibanco Holding S.A. raised its position in Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 104 shares during the period. Cerity Partners LLC lifted its stake in Repligen by 6.1% in the 4th quarter. Cerity Partners LLC now owns 2,718 shares of the biotechnology company’s stock worth $445,000 after acquiring an additional 157 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Repligen by 15.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,327 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Barclays raised their target price on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Canaccord Genuity Group reduced their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research note on Monday, April 20th. Jefferies Financial Group restated a “hold” rating and issued a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th. Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average price target of $165.36.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.